Sectors
NAMS
NewAmsterdam Pharma Company N.V.
28.00
1 x 27.77
1 x 27.92
bid
ask
+
0.02
0.07%
09:38 AM
timesize
| Ytd | -20.18% | |
| 1y | 14.90% |
27.75
day range
28.20
23.95
52 week range
41.45
| Open | 28.00 | Prev Close | 27.98 | Low | 27.75 | High | 28.20 | Mkt Cap | 3.29B |
| Vol | 28.10K | Avg Vol | 1.18M | EPS | -1.96 | P/E | -14.34 | Forward P/E | -18.21 |
| Beta | 0.10 | Short Ratio | 8.63 | Inst. Own | 104.15% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 31.31 | 200-d Avg | 33.55 | 1yr Est | 51.33 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-04 | 2026-09 | -0.5 | N/A | N/A | N/A |
| 2026-08-05 | 2026-06 | -0.48 | -0.52 | -0.04 | -7.90% |
| 2026-05-07 | 2026-03 | -0.46 | -0.4 | 0.06 | 13.04% |
| 2026-02-18 | 2025-12 | -0.43 | -0.63 | -0.2 | -45.09% |
| 2025-11-05 | 2025-09 | -0.38 | -0.41 | -0.03 | -7.89% |
| 2025-08-06 | 2025-06 | -0.52 | -0.15 | 0.37 | 71.15% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-06 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-06-30 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-02-19 | Guggenheim | Upgrade | Buy | Buy |
| 2026-02-18 | Needham | Upgrade | Buy | Buy |
| 2026-01-21 | RBC Capital | Upgrade | Outperform | Outperform |
| 2025-12-16 | Stifel | Upgrade | Buy | Buy |
Profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-01-06 | AUDET JULIETTE BERANGERE | Officer | 15.10K | Stock Award(Grant) |
| 2026-03-01 | DAVIDSON MICHAEL H | Chief Executive Officer | 174.14K | Conversion of Exercise of derivative security |
| 2024-12-29 | FORGROWTH NAP B.V. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2025-01-06 | JONES WILLIAM A JR | Officer | 43.00K | Stock Award(Grant) |
| 2026-03-08 | KASTELEIN JOHANNES JACOB PIETER | Officer and Director | 0.00 | Conversion of Exercise of derivative security |
| 2025-07-15 | KLING DOUGLAS F | Chief Operating Officer | 44.00K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Frazier Life Sciences Management, L.P. | 16.94M | 473.75M | 14.17% |
| 2026-03-30 | Capital World Investors | 11.11M | 310.61M | 9.29% |
| 2026-03-30 | RA Capital Management, L.P. | 9.55M | 267.02M | 7.99% |
| 2026-03-30 | FCPM III Services B.V. | 9.20M | 257.20M | 7.70% |
| 2026-03-30 | FMR, LLC | 8.77M | 245.09M | 7.33% |
| 2026-03-30 | Bain Capital Life Sciences Investors, LLC | 7.31M | 204.29M | 6.11% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | SmallCap World Fund Inc | 8.40M | 234.75M | 7.02% |
| 2026-04-29 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.43M | 95.79M | 2.87% |
| 2026-06-29 | Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 2.19M | 61.26M | 1.83% |
| 2026-06-29 | Fidelity Contrafund | 1.68M | 47.10M | 1.41% |
| 2026-06-29 | New Economy Fund | 957.48K | 26.77M | 0.80% |
| 2026-06-29 | Fidelity Select Portfolios-Select Health Care Portfolio | 750.00K | 20.97M | 0.63% |